MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Dynavax Technologies Corporation Revenue 2011-2026 | DVAX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Dynavax Technologies Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 277 M | 232 M | 723 M | 439 M | 46.6 M | 35.2 M | 8.2 M | 327 K | 11 M | 4.05 M | 11 M | 11.3 M | 9.71 M | 21.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 723 M | 327 K | 131 M |
Quarterly Revenue Dynavax Technologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94.9 M | 95.4 M | 68.2 M | - | 80.6 M | 73.8 M | 50.8 M | - | 69.5 M | 60.2 M | 46.9 M | - | 168 M | 256 M | 114 M | - | 108 M | 52.8 M | 83.3 M | - | 13.4 M | 2.67 M | 10.9 M | 10.6 M | 10.6 M | 8.3 M | 5.77 M | 5.32 M | 1.46 M | 1.25 M | 165 K | 21 K | 53 K | 105 K | 148 K | 7.29 M | 162 K | 2.65 M | 942 K | 685 K | 1.19 M | 1.55 M | 627 K | 2.28 M | 2.21 M | 3.05 M | 3.5 M | 2.85 M | 2.93 M | 3.39 M | 2.08 M | 1.81 M | 2.87 M | 2.68 M | 2.35 M | 11.4 M | 1.17 M | 7.27 M | 1.74 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 256 M | 21 K | 28.9 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.6 | 1.34 % | $ 8.66 B |  Australia |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.66 | - | $ 16.7 M |  USA |
 |
BioNTech SE
BNTX
|
482 M | $ 91.28 | - | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Burford Capital Limited
BUR
|
330 M | $ 4.48 | - | $ 736 M |  Britain |
 |
Cerus Corporation
CERS
|
234 M | $ 1.85 | - | $ 353 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.67 | - | $ 196 M | USA |
 |
Celldex Therapeutics
CLDX
|
1.54 M | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
15.6 M | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Catalyst Pharmaceuticals
CPRX
|
589 M | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
882 K | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
593 K | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
9.44 M | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
7.7 M | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
3.51 M | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
76.2 M | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
90 K | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
27.5 M | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
5.64 M | $ 20.36 | - | $ 2.84 B | France |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Denali Therapeutics
DNLI
|
331 M | $ 19.38 | - | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
3.09 M | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Entera Bio Ltd.
ENTX
|
365 K | $ 1.19 | - | $ 55.5 M | Israel |
 |
Equillium
EQ
|
41.1 M | $ 2.01 | - | $ 115 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
3.71 B | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
6.65 M | $ 1.19 | - | $ 141 M | USA |